A Study To Evaluate The Safety And Tolerability Of Different Doses Of PF-03049423 In Healthy Adult Volunteers And Healthy Older Volunteers

• Drug: PF-03049423
  
  PF-03049423 in oral solution, 2.5 mg, given once daily for 14 days; healthy young adult volunteers
• Drug: PF-03049423
  
  PF-03049423 in oral solution, 7.5 mg, given once daily for 14 days; healthy young adult volunteers
• Drug: PF-03049423
  
  PF-03049423 in oral solution, 6 mg, given once daily for 7 days, then 12 mg given once daily for 7 days; healthy young adult volunteers
• Drug: PF-03049423
  
  PF-03049423 in oral solution, 3 mg, given once daily for 7 days, then 6 mg given once daily for 7 days; healthy elderly adult volunteers
• Drug: PF-03049423
  
  PF-03049423 in oral solution, 5 mg, given once daily for 7 days, then 10 mg given once daily for 7 days; healthy elderly adult volunteers
• Drug: Placebo
  
  Placebo in oral solution, given once daily for 14 days

• Active Comparator: PF-03049423
  
  Cohorts 1 through 3 were healthy young adult volunteers; cohorts 4 and 5 were healthy elderly adult volunteers
  Interventions:
  

  • Drug: PF-03049423
  • Drug: PF-03049423
  • Drug: PF-03049423
  • Drug: PF-03049423
  • Drug: PF-03049423
• Placebo Comparator: Drug
  
  Placebo in oral solution, given once daily for 14 days
  Intervention: Drug: Placebo

Inclusion Criteria:

• Healthy persons, male or female.
• For the healthy young adult cohort, subjects must be 18 to 50 years old, inclusive.
• For the healthy elderly adult cohort, subjects must be 51 to 99 years old, inclusive.
• Body Mass Index (BMI) of 18 to 35; and a total body weight >50 kg (110 lbs)

Exclusion Criteria:

• Subjects with clinically significant medical conditions.
• Women of non-child bearing potential.
• Subjects with a known medical history of hearing loss/disability or nonarteritic ischemic optic neuropathy.
• A positive urine drug screen.